Aldosterone

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 464165

CAS#: 52-39-1

Description: Aldosterone is a mineralocorticoid hormone produced by aldosterone synthase (CYP11B2) in the zona glomerulosa of the adrenal cortex.

Chemical Structure

img
Aldosterone
CAS# 52-39-1
Instruction

Theoretical Analysis

MedKoo Cat#: 464165
Name: Aldosterone
CAS#: 52-39-1
Chemical Formula: C21H28O5
Exact Mass: 360.19
Molecular Weight: 360.450
Elemental Analysis: C, 69.98; H, 7.83; O, 22.19

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Aldosterone;

IUPAC/Chemical Name: (8S,9S,10R,11S,13R,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10-methyl-3-oxo-1,2,3,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-13H-cyclopenta[a]phenanthrene-13-carbaldehyde

InChi Key: PQSUYGKTWSAVDQ-ZVIOFETBSA-N

InChi Code: InChI=1S/C21H28O5/c1-20-7-6-13(24)8-12(20)2-3-14-15-4-5-16(18(26)10-22)21(15,11-23)9-17(25)19(14)20/h8,11,14-17,19,22,25H,2-7,9-10H2,1H3/t14-,15-,16+,17-,19+,20-,21+/m0/s1

SMILES Code: O=C[C@@]12[C@@H](C(CO)=O)CC[C@@]1([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3([H])[C@@H](O)C2)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
Soluble in DMSO 0.0 100.00

Preparing Stock Solutions

The following data is based on the product molecular weight 360.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hanff TC, Cohen JB, Zhao L, Javaheri A, Zamani P, Prenner SB, Rietzschel E, Jia Y, Walsh A, Maranville J, Wang Z, Adam L, Ramirez-Valle F, Schafer P, Seiffert D, Gordon DA, Cvijic ME, Cappola TP, Chirinos JA. Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction. JACC Basic Transl Sci. 2021 Feb 10;6(2):89-99. doi: 10.1016/j.jacbts.2020.11.011. PMID: 33665511; PMCID: PMC7907637.

2: Beldhuis IE, Myhre PL, Bristow M, Claggett B, Damman K, Fang JC, Fleg JL, McKinlay S, Lewis EF, O'Meara E, Pitt B, Shah SJ, Vardeny O, Voors AA, Pfeffer MA, Solomon SD, Desai AS. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. J Am Coll Cardiol. 2021 Mar 9;77(9):1211-1221. doi: 10.1016/j.jacc.2020.12.057. PMID: 33663739.

3: Ramirez-Jimenez M, Morales-Palomo F, Moreno-Cabañas A, Alvarez-Jimenez L, Ortega JF, Mora-Rodriguez R. Effects of antihypertensive medication and high- intensity interval training in hypertensive metabolic syndrome individuals. Scand J Med Sci Sports. 2021 Mar 4. doi: 10.1111/sms.13949. Epub ahead of print. PMID: 33662166.

4: Perkins BA, Lovblom LE, Lanctôt SO, Lamb K, Cherney DZI. Discoveries from the study of longstanding type 1 diabetes. Diabetologia. 2021 Mar 4. doi: 10.1007/s00125-021-05403-9. Epub ahead of print. PMID: 33661335.

5: Khoury EE, Knaney Y, Fokra A, Kinaneh S, Azzam Z, Heyman SN, Abassi Z. Pulmonary, cardiac and renal distribution of ACE2, furin, TMPRSS2 and ADAM17 in rats with heart failure: Potential implication for COVID-19 disease. J Cell Mol Med. 2021 Mar 4. doi: 10.1111/jcmm.16310. Epub ahead of print. PMID: 33660945.

6: Hundemer GL, Kline GA, Leung AA. How common is primary aldosteronism? Curr Opin Nephrol Hypertens. 2021 Mar 1. doi: 10.1097/MNH.0000000000000702. Epub ahead of print. PMID: 33660617.

7: Caroccia B, Vanderriele PE, Seccia TM, Piazza M, Lenzini L, Prisco S, Torresan F, Domening O, Iacobone M, Poglitsch M, Rossi GP. Aldosterone and cortisol synthesis regulation by angiotensin-(1-7) and angiotensin-converting enzyme 2 in the human adrenal cortex. J Hypertens. 2021 Mar 1. doi: 10.1097/HJH.0000000000002816. Epub ahead of print. PMID: 33657582.

8: Takeda Y, Demura M, Wang F, Karashima S, Yoneda T, Kometani M, Aomo D, Hashimoto A, Horike SI, Meguro-Horike M, Takeda Y. Effect of potassium on DNA methylation of aldosterone synthase gene. J Hypertens. 2021 Mar 3. doi: 10.1097/HJH.0000000000002742. Epub ahead of print. PMID: 33657579.

9: Cice G, Monzo L, Calo L. The uraemic hypertensive patient: a therapeutic challenge-right you are (if you think so). Eur Heart J Suppl. 2020 Nov 18;22(Suppl L):L44-L48. doi: 10.1093/eurheartj/suaa133. PMID: 33654466; PMCID: PMC7904065.

10: Katsu Y, Shariful IMD, Lin X, Takagi W, Urushitani H, Kohno S, Hyodo S, Baker ME. N-terminal Domain Regulates Steroid Activation of Elephant Shark Glucocorticoid and Mineralocorticoid Receptors. J Steroid Biochem Mol Biol. 2021 Feb 27:105845. doi: 10.1016/j.jsbmb.2021.105845. Epub ahead of print. PMID: 33652098.

11: Zhang Q, Pan Y, Ma X, Yang H, Chang J, Hong L, Yan H, Zhang SH. Elevated Secretion of Aldosterone Increases TG/HDL-C Ratio and Potentiates The Ox-LDL- Induced Dysfunction of HUVEC. Cell J. 2021 Apr;23(1):61-69. doi: 10.22074/cellj.2021.7033. Epub 2021 Mar 1. PMID: 33650821.

12: Essigke D, Ilyaskin AV, Wörn M, Bohnert BN, Xiao M, Daniel C, Amann K, Birkenfeld AL, Szabo R, Bugge TH, Korbmacher C, Artunc F. Zymogen-locked mutant prostasin (Prss8) leads to incomplete proteolytic activation of the epithelial sodium channel (ENaC) and severely compromises triamterene tolerance in mice. Acta Physiol (Oxf). 2021 Mar 1:e13640. doi: 10.1111/apha.13640. Epub ahead of print. PMID: 33650216.

13: Santos A, Magro DO, Evangelista-Poderoso R, Saad MJA. Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. Diabetol Metab Syndr. 2021 Mar 1;13(1):23. doi: 10.1186/s13098-021-00639-2. PMID: 33648564; PMCID: PMC7919999.

14: Zhou X, Cui H, Zhang Q, Hayat K, Yu J, Hussain S, Tahir MU, Zhang X, Ho CT. Taste improvement of Maillard reaction intermediates derived from enzymatic hydrolysates of pea protein. Food Res Int. 2021 Feb;140:109985. doi: 10.1016/j.foodres.2020.109985. Epub 2020 Dec 16. PMID: 33648220.

15: Nishiwaki H, Niihata K, Shimizu S, Shibagaki Y, Yamamoto R, Nitta K, Tsukamoto T, Uchida S, Takeda A, Okada H, Narita I, Isaka Y, Kurita N; Japan Nephrotic Syndrome Cohort Study group. Incidence and factors associated with prescribing renin-angiotensin-system inhibitors in adult idiopathic nephrotic syndrome: A nationwide cohort study. J Clin Hypertens (Greenwich). 2021 Mar 1. doi: 10.1111/jch.14224. Epub ahead of print. PMID: 33645883.

16: Teragawa H, Oshita C, Orita Y, Hashimoto K, Nakayama H, Yamazaki Y, Sasano H. Primary aldosteronism due to bilateral micronodular hyperplasia and concomitant subclinical Cushing's syndrome: A case report. World J Clin Cases. 2021 Feb 16;9(5):1119-1126. doi: 10.12998/wjcc.v9.i5.1119. PMID: 33644175; PMCID: PMC7896658.

17: Pironti G, Andersson DC, Lund LH. Mechanistic and Therapeutic Implications of Extracellular Vesicles as a Potential Link Between Covid-19 and Cardiovascular Disease Manifestations. Front Cell Dev Biol. 2021 Feb 11;9:640723. doi: 10.3389/fcell.2021.640723. PMID: 33644077; PMCID: PMC7905102.

18: Nakano Y, Iwata N, Ogura-Ochi K, Hasegawa K, Hirasawa A, Otsuka F. Preclinical diagnosis and identification of the chimeric CYP11B1/CYP11B2 gene in two pediatric cases of a Japanese family with glucocorticoid-remediable aldosteronism. Hypertens Res. 2021 Mar 1. doi: 10.1038/s41440-021-00633-1. Epub ahead of print. PMID: 33642567.

19: Kario K, Hettrick DA, Prejbisz A, Januszewicz A. Obstructive Sleep Apnea- Induced Neurogenic Nocturnal Hypertension: A Potential Role of Renal Denervation? Hypertension. 2021 Mar 1:HYPERTENSIONAHA12016378. doi: 10.1161/HYPERTENSIONAHA.120.16378. Epub ahead of print. PMID: 33641363.

20: Adolf C, Görge V, Heinrich DA, Hoster E, Schneider H, Handgriff L, Künzel H, Sturm L, Beuschlein F, Reincke M. Altered Taste Perception for Sodium Chloride in Patients With Primary Aldosteronism: A Prospective Cohort Study. Hypertension. 2021 Mar 1:HYPERTENSIONAHA12016440. doi: 10.1161/HYPERTENSIONAHA.120.16440. Epub ahead of print. PMID: 33641355.